Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jolanta Krajewska, Aleksandra Kukulska, Malgorzata Oczko-Wojciechowska & Barbara Jarzab. (2021) Recent advances in precision medicine for the treatment of medullary thyroid cancer. Expert Review of Precision Medicine and Drug Development 6:5, pages 307-315.
Read now
Read now
Articles from other publishers (8)
Viktoria Florentine Koehler, Pia Adam, Carmina Teresa Fuss, Linmiao Jiang, Elke Berg, Karin Frank-Raue, Friedhelm Raue, Eva Hoster, Thomas Knösel, Hans-Ulrich Schildhaus, Thomas Negele, Udo Siebolts, Kerstin Lorenz, Stephanie Allelein, Matthias Schott, Christine Spitzweg & Matthias Kroiss. (2022) Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors—A Retrospective Multi-Center Registry Analysis. Cancers 14:14, pages 3405.
Crossref
Crossref
Asmaa Raafat, Samar Mowafy, Sahar M. Abouseri, Marwa A. Fouad & Nahla A. Farag. (2022) Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation. Computers in Biology and Medicine 146, pages 105526.
Crossref
Crossref
Viktoria F. KoehlerPia AdamKarin Frank-RaueFriedhelm RaueElke BergEva HosterStephanie AlleleinMatthias SchottMatthias KroissChristine Spitzweg. (2021) Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Thyroid 31:3, pages 459-469.
Crossref
Crossref
Zhengsheng Zhan, Xia Peng, Qiufeng Liu, Fang Chen, Yinchun Ji, Shanyan Yao, Yong Xi, Yipeng Lin, Tiantian Chen, Yechun Xu, Jing Ai, Meiyu Geng & Wenhu Duan. (2016) Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3- b ][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor. European Journal of Medicinal Chemistry 116, pages 239-251.
Crossref
Crossref
Yuanxiang Wang, Jing Ai, Ying Wang, Yi Chen, Lu Wang, Gang Liu, Meiyu Geng & Ao Zhang. (2011) Synthesis and c-Met Kinase Inhibition of 3,5-Disubstituted and 3,5,7-Trisubstituted Quinolines: Identification of 3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a Novel Anticancer Agent. Journal of Medicinal Chemistry 54:7, pages 2127-2142.
Crossref
Crossref
Andrea Morandi, Ivan Plaza-Menacho & Clare M. Isacke. (2011) RET in breast cancer: functional and therapeutic implications. Trends in Molecular Medicine 17:3, pages 149-157.
Crossref
Crossref
Michael Mannion, Stéphane Raeppel, Stephen Claridge, Nancy Zhou, Oscar Saavedra, Ljubomir Isakovic, Lijie Zhan, Frédéric Gaudette, Franck Raeppel, Robert Déziel, Normand Beaulieu, Hannah Nguyen, Ian Chute, Carole Beaulieu, Isabelle Dupont, Marie-France Robert, Sylvain Lefebvre, Marja Dubay, Jubrail Rahil, James Wang, Hélène Ste-Croix, A. Robert Macleod, Jeffrey M. Besterman & Arkadii Vaisburg. (2009) N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 19:23, pages 6552-6556.
Crossref
Crossref
Stéphane Raeppel, Stephen Claridge, Oscar Saavedra, Frédéric Gaudette, Lijie Zhan, Michael Mannion, Nancy Zhou, Franck Raeppel, Marie-Claude Granger, Ljubomir Isakovic, Robert Déziel, Hannah Nguyen, Normand Beaulieu, Carole Beaulieu, Isabelle Dupont, Marie-France Robert, Sylvain Lefebvre, Marja Dubay, Jubrail Rahil, James Wang, Hélène Ste-Croix, A. Robert Macleod, Jeffrey Besterman & Arkadii Vaisburg. (2009) N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 19:5, pages 1323-1328.
Crossref
Crossref